Close

Needham & Company Reiterates Buy on Argos Therapeutics (ARGS) Following Investor Day

December 8, 2016 7:23 AM EST
Get Alerts ARGS Hot Sheet
Price: $0.10 --0%

Rating Summary:
    2 Buy, 4 Hold, 0 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 13 | Down: 11 | New: 11
Join SI Premium – FREE

Needham & Company reiterates a Buy rating and $10.00 price target on Argos Therapeutics (NASDAQ: ARGS) following an investor day. Argos announced they have signed a letter of intent for a 40,000 sq ft leased facility at the Center for Technology Innovation (CTI) at the University of North Caroline to support its AGS-003 launch. The IDMC will meet in February for the next and last ADAPT interim analysis. Final data is expected in late 2Q17.

Analyst Chad Messer commented, "Argos Therapeutics hosted an Investor Day where they provided details on their commercial and manufacturing plans for AGS-003 (Rocapuldencel-T). We are positively inclined to Argos' plans for a targeted launch and confident that they now have a balanced and flexible plan to address commercial manufacturing. The Phase III ADAPT trial testing AGS-003 in metastatic renal cell carcinoma (RCC) is on track for a final interim in February and full data in 2Q17. We remain confident in the Phase III readout and reiterate our Buy rating."

For an analyst ratings summary and ratings history on Argos Therapeutics click here. For more ratings news on Argos Therapeutics click here.

Shares of Argos Therapeutics closed at $4.85 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Analyst Comments

Related Entities

Needham & Company